In 2004, Gunn added a regular segment on biotechnology, BioTech Nation. It has emerged as the only regular weekly mainstream programming on biotech on the national and international scene, and features interviews with biotech leaders. In its regular feature: “BioIssue of the Week”, Gunn discusses the breaking news of the day with award-winning science journalist, David Ewing Duncan.
In the U.S., Tech Nation can be heard four times each weekend on the National Public Radio website’s 24-hour Program Stream (npr.org). It airs on nearly 200 public radio stations, with multiple airtimes on the NPR Channels on XM-Sirius Satellite Radio. Globally, Tech Nation is aired three times weekly on the NPR Channels of Sirius Internet Radio and airs 25 weekly to 177 countries via Armed Forces Radio International. Tech Nation podcasts remain permanently archived on the Internet, enabling anyone, anywhere to listen to these materials on demand.
-
Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, we hear Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talk about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.
-
This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.
-
This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.
-
On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy, and how a discovery made over two decades ago started it all. Now, with a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a pathway to treating aggressive cancers...
-
This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without the need for immunosuppressant drugs.
-
On this episode of BioTech Nation...The Biotech landscape is ever-evolving - but where are we headed?? Dr. Jeremy Levin, Physician, Bioentrepreneur, and Former Chair of BIO, joins Moira to talk about the future of Biotech from the front lines of the industry - from understanding the global Bioeconomy, to preparing for the next pandemic, and how government policy is impacting innovation. His book is, "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust".
-
This week on BioTech Nation, a call to a man who survived hundreds of venomous snake bites helps inspire the development of an antivenom vaccine. Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years.
-
On this week's BioTech Nation, Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the trend of "hospital-at-home". As we see the expansion of remote healthcare technologies, could the future of hospital-like care be as on-demand as a food delivery app?
-
On this episode of BioTech Nation: how Syndax Pharmaceuticals got two new drugs approved in the last two years, for the treatment of acute myeloid leukemia and graft vs. host disease in both adults and children. CEO Michael Metzger talks to Moira about Syndax's approach to getting the drugs across the finish line, and how they've now set their sights on additional indications and cancer therapies.
-
On this episode of BioTech Nation, Dan Schmitt of Actuate Therapeutics talks about a new kind of drug showing positive early results in hard-to-treat cancer - including adult pancreatic cancer, and two pediatric cancers. So, what’s next? Global collaborations, international trials, and efforts into different types of cancer…and they’re showing no sign of slowing down.